BBP-398 clinical trials
Also written BBP-398 and IACS-15509.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses BBP-398 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Navire Pharma Inc., a BridgeBio company (3) · LianBio LLC (2) · Bristol-Myers Squibb (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BBP-398 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid TumorsTerminatedPhase 1/2Bristol-Myers SquibbNCT06024174Written as BMS-986466
- SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C MutationTerminatedPhase 1Navire Pharma Inc., a BridgeBio companyNCT05480865Written as BBP-398
- First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid TumorsTerminatedPhase 1Navire Pharma Inc., a BridgeBio companyNCT04528836Written as BBP-398 (Formerly known as IACS-15509)
- SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS MutationTerminatedPhase 1Navire Pharma Inc., a BridgeBio companyNCT05375084Written as BBP-398 with nivolumab
- Phase I Study of the BBP-398 in Patients With Advance Solid TumorsTerminatedPhase 1LianBio LLCNCT05621525Written as BBP-398
- BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR MutationsTerminatedPhase 1LianBio LLCNCT06032936Written as BBP-398
Codes
What other systems call BBP-398 · ClinicalTrials.gg INT016193
- UNII (FDA) C825F38B80BBP-398One source FDA
- NCI Thesaurus C177417SHP2 Inhibitor BBP-398One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C825F38B80 | BBP-398 | One source FDA |
| NCI Thesaurus | C177417 | SHP2 Inhibitor BBP-398 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.